Your Yourlocation: Home > FDA approved tiotropium bromide(136310-93-5) inhalation aerosol for asthma maintenance treatment

Since 2014, tiotropium bromide(136310-93-5) has been approved for use in asthma in more than 50 countries, including the United States and Japan." US FDA approved tiotropium for asthma has established a new paradigm of inhaled asthma treatment that provides patients with an effective new treatment option. Extensive clinical evidence suggests that tiotropium bromide(136310-93-5) can improve despite the use of ICS /LABA maintenance treatment but still the end of the symptoms of asthma patients. Tiotropium bromide was included in the latest updated GINA global asthma management strategy is a good evidence. Boehringer Ingelheim, director of respiratory medicine, said Dr. Mezzanotte.

The US FDA approved the Boehringer Ingelheim Spiriva Respimat (tiotropium bromide(136310-93-5)) inhalation aerosol for asthma treatment. This drug is approved by the FDA for long-term, daily maintenance for asthma in patients aged 12 years and over. Since the previous regulatory approval, tiotropium diffusing inhalants have been incorporated into the recently updated Global Asthma Reporting Initiative (GINA) Global Strategy for Asthma Management and Prevention in 2015.

While receiving treatment, there are still about half of the asthma patients experiencing symptoms, which makes them at risk of increasing the risk of life-threatening asthma. The key Phase 3 study showed that tiotropium bromide(136310-93-5) as an adjuvant therapy for ICS /LABA maintenance therapy significantly improved the symptoms of asthma and reduced the risk of severe asthma episodes by 20%. The likelihood of improved asthma control was also increased by 68%.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved